Stifel maintains Neurocrine Bio stock target, positive on Takeda deal
Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...
The Pharma Letter2d
Neurocrine revamps osavampator deal with Takeda
USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...
Neurocrine’s Strategic Partnership with Takeda: A Catalyst for Growth and Financial Upside
Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...
BioSpace2d
Neurocine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...
Pharmabiz1d
Neurocrine Biosciences and Takeda amend strategic collaboration to develop and commercialize osavampator
Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...
Neurocrine announces amendment to collaboration with Takeda
Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...
Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences
Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...